Published on: Jan 06, 2026
The ARCADIA consortium, supported by £3 million in funding from Arthritis UK, brings together leading inflammatory arthritis researchers from the UK and Italy to address a critical question: when is true remission achieved? The findings could enable patients to safely stop medication at the right time in the future.
Currently, there is no reliable biological test to confirm whether inflammatory arthritis has fully resolved at the joint level. As a result, some patients may remain on treatment unnecessarily, while others stop medication too early and experience relapse. ARCADIA aims to change this by conducting clinical studies to accurately identify the true absence of disease.
The consortium includes researchers and clinicians from multiple UK universities and hospitals, alongside collaborators in Rome. Their work will focus on understanding inflammatory arthritis—such as rheumatoid arthritis and juvenile idiopathic arthritis—which affects more than 1 in 100 people, including children, and can significantly impact quality of life.
Driven by patient priorities, the study will develop tools to predict relapse risk and redefine remission in a way that reflects long-term wellbeing, not just symptom control. By advancing understanding of disease mechanisms, ARCADIA also aims to accelerate the development of more effective treatments and move closer to a cure.
Back to News
Empowering Innovation Through Global Conferences and Events.
© 2025 SciInov. All Rights Reserved.